Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 5/20 | 0.33 |
| ▸ | IGF1R | P08069 | 6/20 | 0.33 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.33 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.32 |
| ▸ | PLAT | P00750 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | CTSA | P10619 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4145107 | 0.91 | DHODH (0.32) | DHODHIGF1RMRGPRX4MAOBCTSA | |
| SCHEMBL2457673 | 0.85 | DHODH (0.37) | DHODHIGF1RTNK2MRGPRX4HDAC4 | |
| SCHEMBL2459807 | 0.82 | IGF1R (0.47) | DHODHIGF1RTNK2MRGPRX4HDAC4 | |
| SCHEMBL2460636 | 0.82 | IGF1R (0.39) | IGF1RTNK2MRGPRX4MAOB | |
| SCHEMBL2457195 | 0.82 | IGF1R (0.38) | IGF1RTNK2 | |
| SCHEMBL2458683 | 0.82 | IGF1R (0.37) | IGF1RTNK2MRGPRX4PLATMAOB | |
| SCHEMBL2460659 | 0.81 | IGF1R (0.47) | IGF1RTNK2MAOB | |
| SCHEMBL2459711 | 0.81 | IGF1R (0.41) | IGF1RTNK2PLATMAOB | |
| SCHEMBL2457535 | 0.81 | IGF1R (0.38) | IGF1RTNK2MAOB | |
| SCHEMBL2457374 | 0.79 | IGF1R (0.43) | IGF1RTNK2MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675860-B1 | IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS | OSI PHARM INC (US) | 2011-09-21 | — | — | EP | claimed |
| US-20090181940-A1 | Imidazopyrazine Tyrosine Kinase Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181940-A1 | Imidazopyrazine Tyrosine Kinase Inhibitors | IGF1R, IRS1, IGFBP1 | DHODH 3525/4885IGF1R 1/4885TNK2 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.